Dr. Brigitte Poirier is a surgeon-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and a clinical professor at Laval University School of Medicine. Dr. Poirier is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.
Using structured breast cancer data
The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and follow-up of cancers and benign breast diseases.
Offer innovative treatments
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada, offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.
Support the quality of life
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life, despite the adverse effects of the disease on an individual’s life.
1050, chemin Sainte-Foy
Centre des maladies du sein Deschênes-Fabia
Canada G1S 4L8
Data not available
Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patientsJournal Article
Ann Pharmacother, 48 (4), 2014.
Characteristics associated with upgrading to invasiveness after surgery of a DCIS diagnosed using percutaneous biopsyJournal Article
Anticancer Res, 34 (3), 2014.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialJournal Article
Lancet Oncol, 13 (1), 2012.
Low frequency of cancer occurrence in same breast quadrant diagnosed with lobular neoplasia at percutaneous needle biopsyJournal Article
Radiology, 263 (1), 2012.
Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollmentJournal Article
Clin Trials, 9 (5), 2012.
Factors associated with upgrading to malignancy at surgery of atypical ductal hyperplasia diagnosed on core biopsyJournal Article
Breast, 20 (1), 2011.
- NSABP Breast Cancer Treatment Protocols, from 1997-02-01 to 2025-12-25